11/11/2025
Merck's Injectable Version of Blockbuster Cancer Therapy Keytruda Approved by U.S. FDA! The U.S. Food and Drug Administration (FDA) has approved a new formulation of Keytruda (pembrolizumab), Merck's blockbuster cancer medication. The new version, Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph), can be injected subcutaneously, unlike the original Keytruda, which is administered intravenously... https://bit.ly/4qXDZ5O
The U.S. Food and Drug Administration (FDA) has approved a new formulation of Keytruda (pembrolizumab), Merck's blockbuster cancer medication.